Clinical Cancer Research Infection and Cancer: Biology, Therapeutics, and Prevention
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online
This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Yamane, K.
Right arrow Articles by Kinsella, T. J.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Yamane, K.
Right arrow Articles by Kinsella, T. J.
Clinical Cancer Research Vol. 11, 2355-2363, March 2005
© 2005 American Association for Cancer Research

Cancer Therapy: Preclinical

Casein Kinase 2 Regulates Both Apoptosis and the Cell Cycle Following DNA Damage Induced by 6-Thioguanine

Kazuhiko Yamane1 and Timothy J. Kinsella2

1 Department of Radiation Oncology, Case Western Reserve University and 2 University Hospitals of Cleveland, Case Comprehensive Cancer Center, Cleveland, Ohio

Requests for reprints: Timothy J. Kinsella, Department of Radiation Oncology, LTR6068, University Hospitals of Cleveland/Case Comprehensive Cancer Center, 11100 Euclid Avenue, Cleveland, OH 44106-6068. Phone: 216-844-2530; Fax: 216-844-4799; E-mail: timothy.kinsella{at}uhhs.com.


   ABSTRACT
Top
 ABSTRACT
INTRODUCTION
 MATERIALS AND METHODS
 RESULTS
 DISCUSSION
 REFERENCES
 
Purpose: The purine antimetabolite, 6-thioguanine (6-TG), is an effective drug in the management of acute leukemias. In this study, we analyze the mechanisms of apoptosis associated with 6-TG treatment and casein kinase 2 (CK2 or CKII) in human tumor cells.

Experimental Design: Small interfering RNA and chemical CK2 inhibitors were used to reduce CK2 activity. Control and CK2 activity–reduced cells were cultured with 6-TG and assessed by flow cytometry to measure apoptosis and cell cycle profiles. Additionally, confocal microscopy was used to assess localization of CK2 catalytic units following 6-TG treatment.

Results: Transfection of small interfering RNA against the CK2 {alpha} and/or {alpha}' catalytic subunits results in marked apoptosis of HeLa cells following treatment with 6-TG. Chemical inhibitors of CK2 also induce apoptosis following 6-TG treatment. Apoptosis induced by 6-TG is similarly observed in both mismatch repair-proficient and -deficient HCT116 and HeLa cells. Concomitant treatment with a pan-caspase inhibitor or transfection of apoptosis repressor with caspase recruitment domain markedly suppresses the apoptotic response to DNA damage by 6-TG in the CK2-reduced cells, indicating caspase regulation by CK2. CK2 {alpha} relocalizes to the endoplasmic reticulum after 6-TG treatment. Additionally, transfection of Cdc2 with a mutation at Ser39 to Ala, which is the CK2 phosphorylation site, partially inhibits cell cycle progression in G1 to G2 phase following 6-TG treatment.

Conclusion: CK2 is essential for apoptosis inhibition following DNA damage induced by 6-TG, controlling caspase activity.

Key Words: 6-TG • caspase • Casein kinase II • emodin • apigenin • DRB


   INTRODUCTION
Top
 ABSTRACT
 INTRODUCTION
MATERIALS AND METHODS
 RESULTS
 DISCUSSION
 REFERENCES
 
CK2 (formerly, casein kinase II) is a protein Ser/Thr kinase complex that forms a heterotetramer mainly consisting of two catalytic ({alpha} and/or {alpha}') subunits and two noncatalytic (ß) subunits (for recent reviews, see refs. 1, 2). The highly conserved amino acid sequences of CK2 from yeast to humans suggests the importance of CK2 in cellular functions, although its major function(s) is not clearly understood. CK2 is considered to be essential for basic cell viability because a double knock-out of the two catalytic subunits is lethal in yeast (3). In male mice, a knock-out of CK2 {alpha}' is reported to be sterile and related to a defect in spermatogenesis (4). A knock-out of CK2 ß shows embryonic lethality in mice (5). CK2 can interact with Chk1 to increase Cdc25C phosphorylation activity in vitro (6). CK2 also plays an antiapoptotic role by protection of Bid from cleavage by caspase 8 (7).

The purine antimetabolite, 6-thioguanine (6-TG), is an effective chemotherapy drug in the management of acute leukemias (8, 9). However, in spite of 50 years of research, it is still difficult to precisely identify the major mechanism of cytotoxicity. A considerable amount of evidence points to the incorporation of 6-TG into DNA as an initial step in determining cytotoxicity (10). In various mammalian cell lines, 6-TG treatment results in a dose-dependent increase in DNA single-strand breaks, which occur during the second or later cell cycles following initial 6-TG incorporation into DNA (11, 12). Additionally, DNA protein cross-links, DNA double-strand breaks, and a decrease in mRNA synthesis have been reported as other intermediate damage end-points associated with 6-TG cytotoxicity (13, 14).

It is also known that DNA mismatch repair (MMR) plays a role in 6-TG cytotoxicity and that both 6-methyl TG-cytosine and 6-methyl TG-thymidine mismatches are recognized (15). MMR-proficient cells are highly sensitive to 6-TG, showing a prolonged G2-M arrest followed by delayed cell death (16). We recently reported that a 6-TG-induced G2-M arrest involves activation of the ataxia telangiectasia–related-Chk1 pathway and that Chk2 can also be activated and linked to a subsequent tetraploid G1 arrest which blocks cells that escape from the G2-M arrest (17, 18). Thus, these two signaling kinases seem to work cooperatively in MMR-proficient cells to ensure that 6-TG-damaged cells arrest at these cell cycle checkpoints. However, MMR-deficient cells, which do not show a clear G2-M arrest with 6-TG treatment, are also sensitive to higher doses of 6-TG (19). Additionally, although MSH2 knock-out mice were relatively resistant to 6-mercaptopurine treatment compared with wild-type mice, lethality was seen at higher 6-mercaptopurine doses (20), suggesting that these purine antimetabolites (6-TG and 6-mercaptopurine) have dose-related cytotoxicity independent of MMR.

CK2 phosphorylates many substrates including p53 (21), Cdc2 (22) and BRCA1 (23), which can regulate the cell cycle. We recently reported that both BRCA1 and a BRCA1-like protein, TopBP1, could regulate the G2-M checkpoint, partially compensating each function (24). Furthermore, cell cycle progression can be altered by inhibition of CK2 activity (25–27). Therefore, in this study, we examine the role of CK2 in modifying apoptosis and cell cycle regulation following treatment with 6-TG. We find that a reduction of CK2 protein levels by small interfering RNA (siRNA) results in a marked induction of apoptosis and that CK2 also partially regulates cell cycle progression following 6-TG-induced damage.


   MATERIALS AND METHODS
Top
 ABSTRACT
 INTRODUCTION
 MATERIALS AND METHODS
RESULTS
 DISCUSSION
 REFERENCES
 
Cell Culture, Reagents, and Transfection of Small Interfering RNA. HeLa human cervical carcinoma cells, which are known to be MMR-proficient (28), were grown in RPMI 1640 medium supplemented with 10% FCS in a humidified atmosphere of 5% CO2 and 95% air at 37°C. HCT116 human colorectal cancer cells are known to be MMR-deficient because of a hemizygous nonsense mutation in the hMLH1 gene on chromosome 3 (29). HCT116 cells were stably transfected with hMLH1 cDNA or an empty vector to generate an isogenic pair of MMR-proficient (MMR+) and MMR-deficient (MMR–) cells, respectively (30). These HCT116 cells were generously provided by Dr. F. Praz (Centre National de la Recherche, Villejuif, France), and cultured in DMEM supplemented with 10% FCS in a humidified atmosphere of 5% CO2 and 95% air at 37°C. The CK2 chemical inhibitors, apigenin and emodin, and 6-TG were obtained from Sigma (St. Louis, MO) and dissolved in DMSO. The CK2 chemical inhibitor, 5,6-dichloro-1-ß D-ribofuranosyl benzimidazole was obtained from Calbiochem (San Diego, CA). The caspase inhibitor, z-VAD, was obtained from Biomol (Plymouth Meeting, PA).

The anti-CK2 siRNAs used were 5'-GAUGACUACCAGCUGGUUCdTdT ({alpha}), 5'-UCAAGAUGACUACCAGCUGdTdT ({alpha}10, another siRNA against the {alpha} mRNA), and 5'-CAGUCUGAGGAGCCGCGAGdTdT ({alpha}'). The control siRNA was 5'-GCUCAGAUCAAUACGGAGAdTdT. The anti-MSH2 siRNA used was 5'-UCUGCAGAGUGUUGUGCUUdTdT. All siRNAs were obtained from Dharmacon (Lafayette, CO). All were annealed with the complementary strand with dTdT overhangs. Unless stated otherwise, {alpha} (but not {alpha}10) was used for reduction of the {alpha} subunit. Transfections were done with OligofectAMINE, as recommended by the manufacturer (Invitrogen Life Technologies, Carlsbad, CA). Transfection was done for 24 to 30 hours, and HeLa cells were then washed and trypsinized. Next, the cells from one well per 24-well plate were divided into two to three wells and RPMI 1640 medium (and 6-TG when indicated) was added to the culture. The efficiencies of transfection were ~70% to 90% according to the maximum protein level reduction.

Transfection with plasmid DNA was done using Fugene 6, as recommended by the manufacturer (Roche, Indianapolis, IN). This transfection reagent mixed with DNA was incubated with cells during 6-TG treatment. The efficiency of transfection was ~95% according to green fluorescent protein transfection when a tandem or sequential transfection procedure was used. For a tandem transfection, the genes were initially transfected on day 0 and then cells were treated with 6-TG (0 or 3 µmol/L) for 48 hours. A second transfection was done on day 3 and cells were again treated with 6-TG (0 or 3 µmol/L) for another 24 hours.

Western Blotting. Total cell extracts were prepared by trichloroacetic acid precipitation to detect CK2 {alpha} and {alpha}' using specific antibodies (N-18 and C-20, respectively, Santa Cruz Biotechnology, Santa Cruz, CA). An anti-Myc antibody was 9E10 (Babco, Berkeley, CA), anti-ß-actin antibody was from Sigma. After extraction of trichloroacetic acid with ether, the DNA was sheared by sonication before loading onto gels. MLH1 (554072, BD Biosciences, Palo Alto, CA) and MSH2 antibodies (Ab-2, Oncogene Research, San Diego, CA) were also used as controls for the siRNA transfections. The {gamma}-H2AX antibody was obtained from Upstate (Chicago, IL).

Flow Cytometry. Cells were fixed with 90% ethanol at –20°C from 60 minutes to a few days, incubated with RNase, stained with propidium iodide, and then subjected to flow cytometry (Coulter, Epics XL-MCL, Miami, FL). For terminal dUTP nick end labeling (TUNEL) staining, the Apo-Direct kit (eBioscience, San Diego, CA) was used. Typically, at least 10,000 events were counted.

Immunostaining for Confocal Microscopy. HeLa cells were fixed with methanol and acetone (1:1), and then stained with the specific anti-{alpha} or {alpha}' antibodies (N-18 and C-20, respectively; Santa Cruz). Samples were washed and stained with secondary antibodies (Alexa Fluor 633 anti-goat IgG, A21082; Molecular Probes, Eugene, OR) and 4',6-diamidino-2-phenylindole, and then subjected to confocal microscopy (Zeiss Model LSM510; Zeiss, Oberkochen, Germany). Mitotracker (M7514; Molecular Probes) and transfection of endoplasmic reticulum-targeted green fluorescent protein (31) were used for staining of each organelle. The confocal images were obtained with an inverted confocal microscope system (Zeiss) equipped with a tunable T-sapphire laser (Mira-F-V5-XW-220) with a diode pump (Verdi 5 W) to obtain the images with the different dyes. Image analysis was carried out with Adobe Photoshop Software (Adobe Systems, San Jose, CA).

Site-Specific Mutagenesis. Genes encoding apoptosis repressor with caspase recruitment domain (ARC) and Cdc2 were also amplified as described above, and cloned into a pcDNA3-based vector (Invitrogen Life Technologies). The mutations were introduced using Quikchange (Stratagene, La Jolla, CA). All amplified and mutated sequences were confirmed by DNA sequencing in all coding regions.


   RESULTS
Top
 ABSTRACT
 INTRODUCTION
 MATERIALS AND METHODS
 RESULTS
DISCUSSION
 REFERENCES
 
Casein Kinase 2 is Essential for Inhibition of Apoptosis Following 6-Thioguanine Damage. We employed a RNA interference technique (32) for reduction of the protein levels of the CK2 catalytic subunits, mainly using transfection of two siRNAs against both catalytic subunits {alpha} and {alpha}', because the two subunits are reported to have overlapping functions (1). Transfection of the two siRNAs markedly reduced the protein levels of the CK2 {alpha} and {alpha}' subunits, whereas a control siRNA transfection did not (Fig. 1A). Additionally, transfection of a single siRNA directed against either {alpha} or {alpha}' reduced the protein levels of each corresponding subunit (Fig. 1A). The anti-{alpha}' siRNA also slightly reduced the protein level of the {alpha} subunit. The time course experiments indicate that inhibition of CK2 continued at least until day 3 (Fig. 1B). No changes in MSH2, MLH1, and ß-actin protein levels were found following siRNA transfection against {alpha} and/or {alpha}' in HeLa cells.



View larger version (32K):
[in this window]
[in a new window]
  		Fig. 1 The protein levels of CK2 {alpha} and {alpha}' can be reduced by siRNAs. A, HeLa cells were transfected with two different siRNAs against the {alpha} and/or {alpha}' subunits of CK2 as indicated, or with control siRNA for 1 day. The medium was then changed and cells were cultured for 2 days. Total cell lysates were analyzed by Western blotting using antibodies against {alpha} or {alpha}', and ß-actin, respectively; B, time course experiment of the effect of transfection of {alpha} + {alpha}' siRNA was done using the system described above. The protein levels of MSH2 and MLH1 were also determined. The indicated days are cultured days after transfection.

 
After transfection for 1 day, the different transfectants were then treated with 6-TG (15). After continuous exposure to 6-TG (0 or 3 µmol/L) for up to 4 days, the control transfectant showed a predominant G2-M population, whereas the transfectants with siRNAs against both {alpha} and {alpha}' showed a predominant sub-G1 population and a markedly reduced G2-M population (Fig. 2A). We also examined the response to the same 6-TG treatment schedule in HeLa cells following a single siRNA transfection against either the CK2 {alpha} or {alpha}' subunits. For CK2 {alpha}, two different siRNAs ({alpha} and {alpha}10) against {alpha} mRNA were used. Western blotting showed that anti-{alpha}10 siRNA specifically inhibited the protein level of the {alpha} subunit (data not shown). After 4 days of treatment with 6-TG, we found a similar induction of a sub-G1 population following these single siRNA transfections compared with the control (Fig. 2A).



View larger version (25K):
[in this window]
[in a new window]
  		Fig. 2 Reduction of CK2 results in a strong induction of apoptosis after 6-TG treatment. A, HeLa cells transfected with the indicated siRNAs were treated with 6-TG (0 or 3 µmol/L) for up to 4 days. On the indicated days, the cells were fixed and stained with propidium iodide, and analyzed by flow cytometry. {alpha}10 siRNA is targeted to the {alpha} subunit with a nonoverlapping sequence in the {alpha} mRNA; B, similarly transfected HeLa cells were treated with 6-TG as described above for 3 days, fixed with formaldehyde, and then labeled according to the TUNEL method using fluorescein-dUTP. Samples were stained with propidium iodide, and then analyzed by flow cytometry. G0/G1 (G1) and G2-M (G2) populations (arrowheads). The gated regions are TUNEL-positive populations, which are also quantified as the percentage of TUNEL-positive cells per total cell population in the accompanying panels; C, apigenin (20 nmol/L, Sigma), emodin (13 nmol/L, Sigma), or 5,6-dichloro-1-ß D-ribofuranosyl benzimidazole (40 µmol/L, Calbiochem), and/or 6-TG (3 µmol/L, Sigma) were added to the medium of nontransfected HeLa cells for 1 day and then removed. Apigenin (20 nmol/L), emodin (13 nmol/L), or 5,6-dichloro-1-ß D-ribofuranosyl benzimidazole (40 µmol/L) were added again, and the cells were cultured for an additional 3 days.

 
Figure 2B shows that 6-TG treatment (0 or 3 µmol/L) for 3 days in CK2-reduced HeLa cells resulted in a large TUNEL-positive apoptotic population (67%), demonstrating that CK2 is important for inhibition of apoptosis after 6-TG-induced DNA damage. The TUNEL-positive population was significantly lower (29%) following 6-TG treatment in the control cells. Even in the absence of 6-TG damage, a reduction of protein levels of CK2 generated a moderate apoptotic population (21%). It should be noted that the TUNEL-positive populations may not directly correspond to the sub-G1 populations in Fig. 2A, because TUNEL-positive cells are also distributed throughout the cell cycle.

We also used the CK2 chemical inhibitors, apigenin, emodin (33) and 5,6-dichloro-1-ß D-ribofuranosyl benzimidazole (34) to assess the response of CK2 to 6-TG damage in nontransfected HeLa cells (Fig. 2C). However, because we recently reported that the DNA damage response at the G2-M checkpoint requires a long 6-TG treatment period (~4 days) in HeLa cells (17), the CK2 inhibitors alone had significant toxicity, requiring the use of low concentrations for these experiments. Although the data are less clear than those using CK2 siRNAs (Fig. 2A), the CK2 chemical inhibitors also produced an increased sub-G1 population on day 4 with concomitant 6-TG treatment (Fig. 2C). These results also suggest that CK2 activity is required for apoptosis inhibition following 6-TG induced damage.

Casein Kinase 2 {alpha} Relocalizes to the Endoplasmic Reticulum After 6-Thioguanine Treatment. To examine the localization of the CK2 {alpha} or {alpha}' catalytic subunits after 6-TG treatment, we stained nontransfected HeLa cells with the specific anti-CK2 antibodies followed by confocal microscopy. CK2 {alpha} was found to localize in both the nucleus and the cytoplasm without 6-TG treatment (Fig. 3A). However, following 6-TG treatment for 3 days, a large subset of CK2 {alpha} became localized in extranuclear sites. On the other hand, no significant relocalization was found in CK2 {alpha}', although {alpha}' in the cytoplasm was slightly reduced following 6-TG treatment.



View larger version (36K):
[in this window]
[in a new window]
  		Fig. 3 CK2 {alpha} relocalizes to the endoplasmic reticulum after 6-TG treatment. Nontransfected HeLa cells were treated with 0 or 3 µmol/L 6-TG for 3 days and then fixed with methanol and acetone (1:1). Next, the cells were stained with an anti-{alpha} or {alpha}' antibody. Finally, samples were stained with secondary antibodies and 4',6-diamidino-2-phenylindole, and subjected to confocal microscopy; B, Mitotracker and transfection of endoplasmic reticulum-targeted green fluorescent protein were used for staining of the mitochondria and endoplasmic reticulum (ER), respectively.

 
To further investigate the localization change in CK2 {alpha} following 6-TG treatment, Mitotracker and endoplasmic reticulum-targeted green fluorescent protein were used. A majority (but not all) of CK2 {alpha} was localized to the endoplasmic reticulum with significantly less localization in the mitochondria (Fig. 3B). Because the endoplasmic reticulum is reported to participate in the regulation of apoptosis (31), the significance of this localization change is undergoing further investigation.

Apoptosis Can Be Induced by 6-Thioguanine in Both Mismatch Repair-Deficient Cells and -Proficient Cells. We next examined the possible dependency of apoptosis induction by 6-TG on the MMR system, using MMR-deficient and -proficient human colon cancer cells derived from the HCT116 cell line (30). Unexpectedly, the sub-G1 fraction produced by 6-TG treatment was similar in both vector and MLH1 cDNA-transfected HCT116 cells, although MLH1 transfection into MMR– HCT116 cells did significantly change the cell cycle progression in G2-M following 6-TG treatment (Fig. 4A), consistent with our previous data (16–18). The use of hMLH1 siRNA did not result in a significant reduction of MLH1 protein expression in HeLa cells (data not shown). However, although MSH2 siRNA efficiently inhibited the MSH2 protein level in HeLa cells (Fig. 4B), it did not significantly change the extent of apoptosis induction by CK2 siRNA in the presence or absence of 6-TG treatment (Fig. 4B). Similar results of 6-TG-induced apoptosis were also obtained by using three different isogenic pairs of MMR-deficient and -proficient cells, including vector and hMLH1-transfected RKO human tumor cells (16), MSH2 knock-out and MSH2 transfected mouse cells (35), and MSH2-deficient and the MSH2-containing chromosome 2 transferred Hec 59 human tumor cells (ref. 36; and data not shown). However, we did find an enhanced G2-M arrest in the MMR-proficient cells, similar to our prior data (19). These results may be related to the observation that both MMR-deficient and -proficient cells are sensitive to relatively high concentrations of 6-TG (19), and that MSH2-deficient mice are still sensitive to mercaptopurine, another purine antimetabolite used as a chemotherapeutic drug (20).



View larger version (27K):
[in this window]
[in a new window]
  		Fig. 4 6-TG induces similar apoptosis and {gamma}-H2AX damage responses in MMR-deficient and -proficient human tumor cells. A, HCT116 human colon cancer cells, stably transfected with either vector or the hMLH1 gene, were treated with 0 or 3 µmol/L 6-TG for 4 days. Cells were subjected to flow cytometry to measure sub-G1 fractions. Left, the results of two independent experiments; B, mixtures of combined siRNAs (control, MSH2, or {alpha} and {alpha}') were transfected into HeLa cells as indicated. Western blotting was done using the indicated antibodies. Cells were treated as described in (A); C, HCT116 cells, which were stably with transfected either vector or the MLH1 gene, were treated with 3 µmol/L 6-TG for the indicated times. Alternatively, they were irradiated at 10 Gy and cultured for 90 minutes. Total cell lysates were analyzed by Western blotting using a {gamma}-H2AX antibody (Upstate). The exposure time of irradiated samples was five times shorter than that of 6-TG-treated samples.

 
We also checked {gamma}-H2AX levels, a marker of DNA double-strand breaks (37), following 6-TG treatment in the HCT116 vector-only and hMLH1-transfected cells. A moderate induction of {gamma}-H2AX was observed at days 3 and 4 in both MMR-deficient and -proficient cells (Fig. 4C). Ionizing radiation (10 Gy) resulted in a more robust increase (5x) in {gamma}-H2AX expression after 90 minutes to similar levels in both MMR-deficient and -proficient cells. These results suggest that DNA damage induced by 6-TG results in a delayed production of DNA double-strand breaks independent of MMR processing of 6-TG mismatches, consistent with our prior data (16).

A Caspase Inhibitor and Apoptosis Repressor with Caspase Recruitment Domain Inhibit Apoptosis Following 6-Thioguanine Damage. The enhanced apoptotic response in CK2-reduced cells to 6-TG treatment (Fig. 2) suggests that CK2 may regulate apoptosis in the presence of specific chemically induced damage. We next examined the effect of a general caspase inhibitor, z-VAD on this 6-TG effect. When z-VAD was added to CK2-reduced cells, apoptosis was strongly inhibited after 6-TG treatment, suggesting that caspases are involved in the induction of apoptosis (Fig. 5A).



View larger version (27K):
[in this window]
[in a new window]
  		Fig. 5 z-VAD and ARC inhibit apoptosis in CK2-reduced cells after 6-TG treatment. A, the caspase inhibitor z-VAD (Biomol) or the solvent, dimethylsulfoxide, was added to HeLa cells previously transfected with the indicated siRNAs. Cells were also treated simultaneously with 6-TG (0 or 3 µmol/L) for 4 days, and then analyzed by flow cytometry; B, myc epitope-tagged ARC, its mutants, and the vector were transfected into HeLa cells. Proteins were analyzed by Western blotting using an anti-Myc antibody; C, schematic presentation of experiments done in (D); D, HeLa cells were treated with siRNA ({alpha} and {alpha}'), and cultured for 1 day with 6-TG (0 or 3 µmol/L). Wild-type ARC, one of its mutants, or the vector alone were then transfected into HeLa cells. The transfectants were recultured in medium with 6-TG (0 or 3 µmol/L) for 3 days prior to harvest (a single transfection). In the case of a tandem transfection, the genes were initially transfected on day 0, and the cells were then cultured for 2 days with 6-TG (0 or 3 µmol/L). The genes were transfected again on day 3. These cells were then cultured in medium with 6-TG (0 or 3 µmol/L) for 1 additional day prior to harvest for flow cytometry. The plasmid transfection and culture were done simultaneously; E, columns of the percentage of sub-G1 fraction in the various transfections following a tandem or single transfection as described.

 
Additionally, the G2-M population decreased in CK2-reduced cells after 6-TG and z-VAD treatment (Fig. 5A, compare z-VAD+ and 6-TG+), suggesting that CK2 can affect both apoptosis and the cell cycle. Recently, it was reported that ARC can be phosphorylated by CK2 at Thr149, regulating the apoptosis inhibitory function of ARC (38). Therefore, we expressed ARC and its mutants, 149A (Thr to Ala, an unphosphorylatable form) and 149E (Thr to Glu, a phosphorylation-mimicking form) in HeLa cells (Fig. 5B). After treatment with both anti-CK2 {alpha} and {alpha}' siRNAs, the wild-type ARC strongly inhibited apoptosis when the gene was transfected twice (tandem transfection; see protocol in Fig. 5C) in both 6-TG-treated and -nontreated cells (vector and wild-type ARC; Fig. 5D and E), indicating that ARC can also inhibit apoptosis in CK2-reduced cells. It should be noted that the tandem transfection procedures of the vector plasmid did increase the sub-G1 populations (vector, tandem, and single transfection; Fig. 5D and E). However, the mutant ARC transfectants did not show significant differences in the extent of apoptosis compared with the wild-type ARC transfectants. These results suggest that Thr149 is not critical for the inhibition of apoptosis following 6-TG DNA damage, which differs from the apoptosis triggers used in the previous report (38).

Phosphorylation of Cdc2 Ser39 Can Regulate the Cell Cycle after 6-Thioguanine Treatment Cdc2 can be phosphorylated at Ser39 by CK2 in vivo (22). Because Cdc2 is an essential protein involved in cell cycle regulation, we examined whether the cell cycle response to 6-TG-induced DNA damage was changed by a Cdc2 39A mutation (Ser39 was mutated to Ala). When HeLa cells were transfected with the 39A mutant, the G2-M peak induction was partially inhibited after 6-TG treatment (3 µmol/L x 4 days; 62% versus 27%; Fig. 6A). These cell cycle data are also consistent with the results of the effect of z-VAD in CK2-reduced cells (Fig. 5A). It should be noted that Ser39 is close in the three-dimensional structure of Cdc2 to Tyr15 (39), which is critical for Cdc2 regulation. These data suggest that CK2 may participate in a proposed CK2-Cdc2 cell cycle regulatory pathway. CK2 was not involved in a G2-M checkpoint control (data not shown) when we examined this checkpoint using nocodazole as we recently described (17).



View larger version (28K):
[in this window]
[in a new window]
  		Fig. 6 Cdc2 39A partially inhibits cell cycle progression. A, HeLa cells were transfected with the wild-type or a 39A mutant cdc2 (Myc epitope-tagged) gene. Cells were cultured for 4 days in the presence or absence of 3 µmol/L 6-TG. Transfection of wild-type or 39A mutant cdc2 was repeated following day 2 of the 6-TG (0 or 3 µmol/L) treatment. Cells were then fixed and analyzed by flow cytometry. The percentage of each population was analyzed by ModFit. Myc epitope-tagged proteins were also analyzed by Western blotting using an anti-Myc antibody; B, proposed signaling pathways in 6-TG-induced DNA damage. Arrows, possible signal flows.

 

   DISCUSSION
Top
 ABSTRACT
 INTRODUCTION
 MATERIALS AND METHODS
 RESULTS
 DISCUSSION
REFERENCES
 
In this study, we show that apoptosis is strongly enhanced following 6-TG treatment by a reduction of the CK2 catalytic subunits through siRNA transfection (Fig. 2). Transfection of three different siRNAs ({alpha}, {alpha}10, and {alpha}') against CK2 catalytic subunits resulted in a similar induction of apoptosis following 6-TG treatment. The use of three chemical inhibitors of CK2, apigenin, emodin, and 5,6-dichloro-1-ß D-ribofuranosyl benzimidazole (33, 34) also enhanced apoptosis after 6-TG damage in nontransfected cells (Fig. 2). A pan-caspase inhibitor, z-VAD, or cotransfection with ARC, blocked this apoptotic response to 6-TG treatment in CK2-reduced cells, suggesting that CK2 regulates caspase activity (Fig. 5). These results also suggest that a 6-TG-induced DNA damage response involves a CK2-apoptosis inhibitory pathways (Fig. 6B).

The transfectants with wild-type ARC, or its mutants 149A and 149E, show similar levels of apoptosis after 6-TG damage in CK2-reduced cells (Fig. 5D and E). These data suggest that this unique phosphorylation site by CK2 in ARC (38) is not critical for a DNA damage response induced by 6-TG treatment. Therefore, we speculate that CK2 may have other target(s) affecting apoptosis. Interestingly, we found that a subset of CK2 {alpha} became localized to the endoplasmic reticulum following 6-TG treatment (Fig. 3). On the other hand, no significant relocalization was found in CK2 {alpha}'. Currently, we are further investigating the significance of these localization changes of CK2 in this response to 6-TG-induced damage. It is interesting to note that CK2 is required for adaptation of a checkpoint arrest in yeast (40).

We also find that the G2-M population is reduced in the presence of z-VAD and 6-TG in CK2-reduced cells (Fig. 5A). These data are supported by a prior study suggesting that CK2 is required for cell cycle progression during G1 and G2 phases (3). Furthermore, we show that a 39A mutation of Cdc2 partially inhibits cell cycle progression in G1 and G2 following 6-TG treatment (Fig. 6A). Because this site is the phosphorylation site of CK2 in vivo, our results suggest that CK2 partially regulates cell cycle progression during G1 and G2. Thus, it seems that a 6-TG-induced DNA damage response may also involve a CK2-Cdc2 pathway (Fig. 6B). We have tried several times, without success, to generate a phospho-specific antibody against the phosphorylated Cdc2 Ser39. It is possible that the epitope around the site containing similar residues (Ser39-Glu-Glu-Glu) might inhibit the specific antibody production.

Apoptosis was similarly induced by 6-TG in isogenic MMR-deficient and -proficient cells derived from HCT116, suggesting that 6-TG-induced apoptosis is independent of the MMR system (Fig. 4). Consistently, MSH2 siRNA transfection in HeLa cells did not significantly change apoptosis in the presence of 6-TG when CK2 protein levels were reduced (Fig. 4). Our results may be explained by published data that both MMR-deficient and -proficient cells are sensitive to relatively high concentrations of 6-TG (19), and that MSH2-deficient mice are still sensitive to mercaptopurine, another purine antimetabolite (20). However, we do not know the kind of DNA damage that is critical for apoptosis induced by 6-TG in CK2-reduced cells. Because 6-TG treatment also caused a modest induction of {gamma}-H2AX (Fig. 4C), it may be possible that CK2 participates in the different types of 6-TG damage, including DNA double-strand breaks, single-strand breaks, and DNA-protein cross-linking (13, 14). In contrast, our recent study indicated that persistent DNA single-strand breaks produced during MMR processing of 6-TG DNA mismatches are likely the initial chemical signals to an initial MMR-mediated G2-M arrest and later cell death (16).

In conclusion, we have identified two possible pathways involving CK2 in a 6-TG-induced response, a CK2-apoptosis inhibitory pathway and a CK2-Cdc2 pathway. Further elucidation of these proposed pathways may provide insight in our understanding of drug resistance for 6-TG.


   ACKNOWLEDGMENTS
 
We thank Drs. Nancy Oleinick for a critical reading of this manuscript and Song-mao Chiu for discussion; Michael Sramkoski of CWRU for flow cytometry techniques, Drs. Minn Lam and Anna-Liisa Nieminen for confocal microscopy techniques, Clark Distelhorst and Michael Malone for the endoplasmic reticulum targeted-GFP plasmid, Paul Nurse for the cdc2 gene, and Françoise Praz for HCT116-derived cells.


   FOOTNOTES
 
Grant support: NIH grant CA84578 (T.J. Kinsella); Flow Cytometry Core Facility and Confocal Microscopy Core Facility (P30, CA43703-12) of the Case Comprehensive Cancer Center.

The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked advertisement in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.

Received 8/27/04; revised 10/28/04; accepted 11/15/04.


   REFERENCES
Top
 ABSTRACT
 INTRODUCTION
 MATERIALS AND METHODS
 RESULTS
 DISCUSSION
 REFERENCES
 

  1. Litchfield DW. Protein kinase CK2: structure, regulation and role in cellular decisions of life and death. Biochem J 2003;369:1–15.[CrossRef][Medline]
  2. Meggio F, Pinna LA. One-thousand-and-one substrates of protein kinase CK2? FASEB J 2003;17:349–68.[Abstract/Free Full Text]
  3. Hanna DE, Rethinaswamy A, Glover CV. Casein kinase II is required for cell cycle progression during G1 and G2-M in Saccharomyces cerevisiae. J Biol Chem 1995;270:25905–14.[Abstract/Free Full Text]
  4. Xu X, Toselli PA, Russell LD, Seldin DC. Globozoospermia in mice lacking the casein kinase II {alpha}' catalytic subunit. Nat Genet 1999;23:118–21.[CrossRef][Medline]
  5. Buchou T, Vernet M, Blond O, et al. Disruption of the regulatory ß subunit of protein kinase CK2 in mice leads to a cell-autonomous defect and early embryonic lethality. Mol Cell Biol 2003;23:908–15.[Abstract/Free Full Text]
  6. Guerra B, Issinger OG, Wang JY. Modulation of human checkpoint kinase Chk1 by the regulatory ß-subunit of protein kinase CK2. Oncogene 2003;22:4933–42.[CrossRef][Medline]
  7. Desagher S, Osen-Sand A, Montessuit S, et al. Phosphorylation of bid by casein kinases I and II regulates its cleavage by caspase 8. Mol Cell 2001;8:601–11.[CrossRef][Medline]
  8. Bohon J, de los Santos CR. Structural effect of the anticancer agent 6-thioguanine on duplex DNA. Nucleic Acids Res 2003;31:1331–8.[Abstract/Free Full Text]
  9. Elgemeie GH. Thioguanine, mercaptopurine: their analogs and nucleosides as antimetabolites. Curr Pharm Des 2003;9:2627–42.[CrossRef][Medline]
  10. Christie NT, Drake S, Meyn RE, Nelson JA. 6-Thioguanine-induced DNA damage as a determinant of cytotoxicity in cultured Chinese hamster ovary cells. Cancer Res 1984;44:3665–71.[Abstract/Free Full Text]
  11. Pan BF, Nelson JA. Characterization of the DNA damage in 6-thioguanine-treated cells. Biochem Pharmacol 1990;40:1063–9.[CrossRef][Medline]
  12. Fairchild CR, Maybaum J, Kennedy KA. Concurrent unilateral chromatid damage and DNA strand breakage in response to 6-thioguanine treatment. Biochem Pharmacol 1986;35:3533–41.[CrossRef][Medline]
  13. Pan BF, Priebe TS, Nelson JA. Mechanisms of resistance to 6-thioguanine in a murine pancreatic tumor. Cancer Chemother Pharmacol 1992;29:471–4.[CrossRef][Medline]
  14. Ling YH, Chan JY, Beattie KL, Nelson JA. Consequences of 6-thioguanine incorporation into DNA on polymerase, ligase, and endonuclease reactions. Mol Pharmacol 1992;42:802–7.[Abstract]
  15. Swann PF, Waters TR, Moulton DC, et al. Role of postreplicative DNA mismatch repair in the cytotoxic action of thioguanine. Science 1996;273:1109–11.[Abstract]
  16. Yan T, Berry SE, Desai AB, Kinsella TJ. DNA mismatch repair (MMR) mediates 6-thioguanine (6-TG) genotoxcity by introducing single strand breaks to signal a G2/M arrest in MMR-proficient RKO cells. Clin Cancer Res 2003;9:2327–34.[Abstract/Free Full Text]
  17. Yamane K, Taylor K, Kinsella TJ. Mismatch repair-mediated G2-M arrest by 6-thioguanine involves the ATR-Chk1 pathway. Biochem Biophys Res Commun 2004;318:297–302.[CrossRef][Medline]
  18. Yan T, Desai AB, Jacobberger JW, Sramkoski RL, Loh T, Kinsella TJ. CHK1 and CHK2 are differentially involved in mismatch repair-mediated 6-thioguanine-induced cell cycle checkpoint responses. Mol Cancer Ther 2004;3:1–11.[Abstract/Free Full Text]
  19. Yan T, Schupp JE, Hwang HS, et al. Loss of DNA mismatch repair imparts defective cdc2 signaling and G2 arrest responses without altering survival after ionizing radiation. Cancer Res 2001;61:8290–7.[Abstract/Free Full Text]
  20. Krynetskaia NF, Brenner TL, Krynetski EY, et al. Msh2 deficiency attenuates but does not abolish thiopurine hematopoietic toxicity in msh2–/– mice. Mol Pharmacol 2003;64:456–65.[Abstract/Free Full Text]
  21. Meek DW, Simon S, Kikkawa U, Eckhart W. The p53 tumour suppressor protein is phosphorylated at serine 389 by casein kinase II. EMBO J 1990;9:3253–60.[Medline]
  22. Russo GL, Vandenberg MT, Yu IJ, Bae YS, Franza BR Jr, Marshak DR. Casein kinase II phosphorylates p34cdc2 kinase in G1 phase of the HeLa cell division cycle. J Biol Chem 1992;267:20317–25.[Abstract/Free Full Text]
  23. O'Brien KA, Lemke SJ, Cocke KS, Rao RN, Beckmann RP. Casein kinase 2 binds to and phosphorylates BRCA1. Biochem Biophys Res Commun 1999;260:658–64.[CrossRef][Medline]
  24. Yamane K, Chen J, Kinsella TJ. Both DNA topoisomerase II-binding protein 1 and BRCA1 regulate the G2-M cell cycle checkpoint. Cancer Res 2003;63:3049–53.[Abstract/Free Full Text]
  25. Lorenz P, Pepperkok R, Ansorge W, Pyerin W. Cell biological studies with monoclonal and polyclonal antibodies against human casein kinase II subunit ß demonstrate participation of the kinase in mitogenic signaling. J Biol Chem 1993;268:2733–9.[Abstract/Free Full Text]
  26. Pepperkok R, Lorenz P, Ansorge W, Pyerin W. Casein kinase II is required for transition of G0/G1, early G1, and G1/S phases of the cell cycle. J Biol Chem 1994;269:6986–91.[Abstract/Free Full Text]
  27. Rethinaswamy A, Birnbaum MJ, Glover CV. Temperature-sensitive mutations of the CKA1 gene reveal a role for casein kinase II in maintenance of cell polarity in Saccharomyces cerevisiae. J Biol Chem 1998;273:5869–77.[Abstract/Free Full Text]
  28. Marra G, Chang CL, Laghi LA, Chauhan DP, Young D, Boland CR. Expression of human MutS homolog 2 (hMSH2) protein in resting and proliferating cells. Oncogene 1996;13:21899–6.
  29. Koi M, Umar A, Chauhan DP, et al. Human chromosome 3 corrects mismatch repair deficiency and microsatellite instability and reduces N-methyl-N'-nitro-N-nitrosoguanidine tolerance in colon tumor cells with homozygous hMLH1 mutation. Cancer Res 1994;54:4308–12.[Abstract/Free Full Text]
  30. Jacob S, Aguado M, Fallik D, Praz F. The role of the DNA mismatch repair system in the cytotoxicity of the topoisomerase inhibitors camptothecin and etoposide to human colorectal cancer cells. Cancer Res 2001;61:6555–62.[Abstract/Free Full Text]
  31. Thomenius MJ, Wang NS, Reineks EZ, Wang Z, Distelhorst CW. Bcl-2 on the endoplasmic reticulum regulates Bax activity by binding to BH3-only proteins. J Biol Chem 2003;278:6243–50.[Abstract/Free Full Text]
  32. McManus MT, Sharp PA. Gene silencing in mammals by small interfering RNAs. Nat Rev Genet 2002;3:737–47.[CrossRef][Medline]
  33. Channavajhala P, Seldin DC. Functional interaction of protein kinase CK2 and c-Myc in lymphomagenesis. Oncogene 2002;21:5280–8.[CrossRef][Medline]
  34. Izeradjene K, Douglas L, Delaney A, Houghton JA. Influence of casein kinase II in tumor necrosis factor-related apoptosis-inducing ligand-induced apoptosis in human Rhabdomyosarcoma cells. Clin Cancer Res 2004;10:6650–60.[Abstract/Free Full Text]
  35. de Wind N, Dekker M, Berns A, Radman M, te Riele H. Inactivation of the mouse Msh2 gene results in mismatch repair deficiency, methylation tolerance, hyperrecombination, and predisposition to cancer. Cell 1995;82:321–30.[CrossRef][Medline]
  36. Umar A, Koi M, Risinger JI, et al. Correction of hypermutability, N-methyl-N'-nitro-N-nitrosoguanidine resistance, and defective DNA mismatch repair by introducing chromosome 2 into human tumor cells with mutations in MSH2 and MSH6. Cancer Res 1997;57:3949–55.[Abstract/Free Full Text]
  37. Rogakou EP, Boon C, Redon C, Bonner WM. Megabase chromatin domains involved in DNA double-strand breaks in vivo. J Cell Biol 1999;146:905–16.[Abstract/Free Full Text]
  38. Li PF, Li J, Muller EC, Otto A, Dietz R, von Harsdorf R. Phosphorylation by protein kinase CK2: a signaling switch for the caspase-inhibiting protein ARC. Mol Cell 2002;10:247–58.[CrossRef][Medline]
  39. De Bondt HL, Rosenblatt J, Jancarik J, Jones HD, Morgan DO, Kim SH. Crystal structure of cyclin-dependent kinase 2. Nature 1993;363:595–602.[CrossRef][Medline]
  40. Toczyski DP, Galgoczy DJ, Hartwell LH. CDC5 and CKII control adaptation to the yeast DNA damage checkpoint. Cell 1997;90:1097–106.[CrossRef][Medline]



This article has been cited by other articles:


Home page
 J. Biol. Chem.Home page
H. Luo, Y. Li, J.-J. Mu, J. Zhang, T. Tonaka, Y. Hamamori, S. Y. Jung, Y. Wang, and J. Qin
Regulation of Intra-S Phase Checkpoint by Ionizing Radiation (IR)-dependent and IR-independent Phosphorylation of SMC3
J. Biol. Chem., July 11, 2008; 283(28): 19176 - 19183.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
K. Yamane, J. E. Schupp, and T. J. Kinsella
BRCA1 Activates a G2-M Cell Cycle Checkpoint following 6-Thioguanine-Induced DNA Mismatch Damage
Cancer Res., July 1, 2007; 67(13): 6286 - 6292.
[Abstract] [Full Text] [PDF]

Home page
 Molecular Cancer TherapeuticsHome page
K. A. Ahmad, N. H. Harris, A. D. Johnson, H. C.N. Lindvall, G. Wang, and K. Ahmed
Protein kinase CK2 modulates apoptosis induced by resveratrol and epigallocatechin-3-gallate in prostate cancer cells
Mol. Cancer Ther., March 1, 2007; 6(3): 1006 - 1012.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
J. S. Kim, J. I. Eom, J.-W. Cheong, A. J. Choi, J. K. Lee, W. I. Yang, and Y. H. Min
Protein Kinase CK2{alpha} as an Unfavorable Prognostic Marker and Novel Therapeutic Target in Acute Myeloid Leukemia
Clin. Cancer Res., February 1, 2007; 13(3): 1019 - 1028.
[Abstract] [Full Text] [PDF]

This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Yamane, K.
Right arrow Articles by Kinsella, T. J.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Yamane, K.
Right arrow Articles by Kinsella, T. J.

HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online